EBS Quote, Financials, Valuation and Earnings

Chimerix has a net margin of 40.45% compared to Emergent BioSolutions's net margin of -87996.15%. Emergent BioSolutions's return on equity of -35.94% beat Chimerix's return on equity of -48.22%.

Emergent BioSolutions has a consensus price target of $12.00, signalling upside risk potential of 45.1%. On the other hand Chimerix has an analysts' consensus of -- which suggests that it could grow by 142.78%. Given that Chimerix has higher upside potential than Emergent BioSolutions, analysts believe Chimerix is more attractive than Emergent BioSolutions.

Emergent BioSolutions has a beta of 1.594, which suggesting that the stock is 59.352% more volatile than S&P 500. In comparison Chimerix has a beta of 1.018, suggesting its more volatile than the S&P 500 by 1.827%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chimerix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Chimerix pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $283.8M, which are larger than Chimerix quarterly revenues of $26K. Emergent BioSolutions's net income of $114.8M is higher than Chimerix's net income of -$22.9M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Chimerix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.40x versus -- for Chimerix. Usually stocks with elevated PS ratios are considered overvalued.

Geron has a net margin of 40.45% compared to Emergent BioSolutions's net margin of -93.55%. Emergent BioSolutions's return on equity of -35.94% beat Geron's return on equity of -67.86%.

Emergent BioSolutions has a consensus price target of $12.00, signalling upside risk potential of 45.1%. On the other hand Geron has an analysts' consensus of $7.61 which suggests that it could grow by 127.2%. Given that Geron has higher upside potential than Emergent BioSolutions, analysts believe Geron is more attractive than Emergent BioSolutions.

Emergent BioSolutions has a beta of 1.594, which suggesting that the stock is 59.352% more volatile than S&P 500. In comparison Geron has a beta of 0.507, suggesting its less volatile than the S&P 500 by 49.279%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $283.8M, which are larger than Geron quarterly revenues of $28.3M. Emergent BioSolutions's net income of $114.8M is higher than Geron's net income of -$26.4M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.40x versus 71.44x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

MAIA Biotechnology has a net margin of 40.45% compared to Emergent BioSolutions's net margin of --. Emergent BioSolutions's return on equity of -35.94% beat MAIA Biotechnology's return on equity of --.

Emergent BioSolutions has a consensus price target of $12.00, signalling upside risk potential of 45.1%. On the other hand MAIA Biotechnology has an analysts' consensus of $12.63 which suggests that it could grow by 504.07%. Given that MAIA Biotechnology has higher upside potential than Emergent BioSolutions, analysts believe MAIA Biotechnology is more attractive than Emergent BioSolutions.

Emergent BioSolutions has a beta of 1.594, which suggesting that the stock is 59.352% more volatile than S&P 500. In comparison MAIA Biotechnology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MAIA Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. MAIA Biotechnology pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $283.8M, which are larger than MAIA Biotechnology quarterly revenues of --. Emergent BioSolutions's net income of $114.8M is higher than MAIA Biotechnology's net income of -$2.7M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while MAIA Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.40x versus -- for MAIA Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.

Tonix Pharmaceuticals Holding has a net margin of 40.45% compared to Emergent BioSolutions's net margin of -503.65%. Emergent BioSolutions's return on equity of -35.94% beat Tonix Pharmaceuticals Holding's return on equity of -150.01%.

Emergent BioSolutions has a consensus price target of $12.00, signalling upside risk potential of 45.1%. On the other hand Tonix Pharmaceuticals Holding has an analysts' consensus of $5.83 which suggests that it could grow by 1627.88%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Emergent BioSolutions, analysts believe Tonix Pharmaceuticals Holding is more attractive than Emergent BioSolutions.

Emergent BioSolutions has a beta of 1.594, which suggesting that the stock is 59.352% more volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding has a beta of 2.232, suggesting its more volatile than the S&P 500 by 123.214%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $283.8M, which are larger than Tonix Pharmaceuticals Holding quarterly revenues of $2.8M. Emergent BioSolutions's net income of $114.8M is higher than Tonix Pharmaceuticals Holding's net income of -$14.2M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.40x versus 0.53x for Tonix Pharmaceuticals Holding. Usually stocks with elevated PS ratios are considered overvalued.